Rosen & Barkin's 5-Minute Emergency Medicine Consult (197 page)

Read Rosen & Barkin's 5-Minute Emergency Medicine Consult Online

Authors: Jeffrey J. Schaider,Adam Z. Barkin,Roger M. Barkin,Philip Shayne,Richard E. Wolfe,Stephen R. Hayden,Peter Rosen

Tags: #Medical, #Emergency Medicine

BOOK: Rosen & Barkin's 5-Minute Emergency Medicine Consult
9.19Mb size Format: txt, pdf, ePub
PRE HOSPITAL
  • Obtain history from friends, family
  • Provide for patient and staff safety
  • Manage agitation
  • Attentiveness to comorbid conditions
  • Treat acute toxic and metabolic disorders:
    • Hypoglycemia
    • Hypothermia
    • Hyperthermia
INITIAL STABILIZATION/THERAPY
  • Ensure adequate airway
  • Administer O
    2
    if hypoxic
  • Ensure normal vital signs
  • Establish IV access if required
  • In agitated patients, provide for patient and staff safety
ED TREATMENT/PROCEDURES
  • Must determine if patient presents with acute change in mental status
  • Consider full differential diagnosis—evaluate and treat appropriately:
    • Treat hypoglycemia with PO or IV dextrose.
    • Treat narcotic overdose or excess with naloxone.
    • Rewarm if hypothermic.
    • Antipyretic for hyperthermia
    • IV fluids for dehydration
    • Correct electrolyte abnormalities
    • Administer antibiotics for infection:
      • UTI and pneumonia most common occult infections; look for wounds and decubitus ulcers
    • Treat seizures:
      • Lorazepam, other agents as needed
      • Long-term management in conjunction with neurology
  • Sedation for agitation:
    • Start with low doses and increase as necessary to achieve clinical result.
    • Neuroleptics: Haloperidol, risperidone, ziprasidone
    • Benzodiazepines: Lorazepam, midazolam
  • Soft restraints if chemical sedation ineffective
  • Attempt to limit number of medications:
    • Reduced likelihood of toxicity
    • Reduced likelihood of drug–drug interaction
    • If agitation not an issue, eliminate all sedative-hypnotics
  • Treat depression
MEDICATION
  • Alzheimer’s agents: Always start at lowest dose:
    • Donepezil: 5–10 mg PO at bedtime
    • Rivastigmine: 1.5–6 mg PO BID
    • Galantamine: 4–12 mg PO BID
    • Above 3 anticholinergics without clear superior agent, watch for side effects including nausea, vomiting, diarrhea
    • Consider memantine (NMDA receptor antagonist) in those with poor response to anticholinergics: 5 mg PO QID–10 mg PO BID
    • Effects generally modest, best started, and changed by primary provider
    • Numerous trials showing inconsistent or negative benefit of anti-inflammatory agents, estrogens, and statins for Alzheimer
  • Antidepressants: Start with lowest dose:
    • Oversedation a problem
    • May worsen dementia
    • Useful in patients who cannot sleep
  • Sedative agents: Always start with lowest dose
    • Droperidol: 0.625–2.5 mg IV—advantage, rapid onset; disadvantage, risk for QT prolongation
  • Haloperidol: 0.5–2 mg PO BID; start with lowest dose 0.5–2.5 mg IM or IV if rapid onset required
  • Lorazepam: 0.5–1 mg IV, 0.5–2 mg PO
  • Midazolam: 0.5–2 mg IV slow push
  • Naloxone: 0.4–2 mg IVP
  • Risperidone: 0.5–2 mg PO BID; start with lowest dose
  • Ziprasidone: 20–80 mg PO BID, 10–20 mg IM q4h; start with lowest dose
FOLLOW-UP
DISPOSITION
Admission Criteria
  • Unstable vital signs
  • Significant comorbid condition requiring parenteral medications:
    • Pneumonia
    • UTI
    • Fluid and electrolyte disorder
  • Uncertain diagnosis requiring evaluation and management that is not suitable for outpatients
  • Inadequate home support coupled with inability to arrange suitable placement from ED
Discharge Criteria
  • Stable vital signs
  • No significant unstable comorbid conditions
  • Secure diagnosis or elimination of life-threatening organic disease
  • Adequate home support, watch for caregiver burnout
  • Reliable access to follow-up care
Issues for Referral
  • Patients may need assistance with transportation, finances, etc.
  • Patients with other comorbidities need referral to appropriate specialists.
FOLLOW-UP RECOMMENDATIONS
  • Primary care
  • Geriatrician
  • Psychiatrist
  • Neurologist
PEARLS AND PITFALLS
  • Primary dementia is characterized by slow, steady progression:
    • Course is generally 5–10 yr from diagnosis to death.
  • Can fluctuate as consequence of intervening illness and comorbid conditions
  • Cholinesterase medications can improve functional status in patients with Alzheimer disease.
  • Careful attention to medications, secondary illnesses, and prompt intervention for infections can improve quality of life and longevity.
  • Death is generally consequence of infection, cardiovascular disease, or injury.
ADDITIONAL READING
  • Holsinger T, Deveau J, Boustani M, et al. Does this patient have dementia?
    JAMA
    . 2007;297:2391–2404.
  • Langa KM, Foster NL, Larson EB. Mixed dementia: Emerging concepts and therapeutic implications.
    JAMA
    . 2004;292:2901–2908.
  • Mayeux, R. Clinical practice. Early Alzheimer’s disease.
    N Engl J Med
    . 2010;362:2194–2201.
  • Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia.
    N Engl J Med
    . 2009;361:1529–1538.
  • Petersen RC. Mild cognitive impairment.
    N Engl J Med
    . 2011;364:2227–2234.
  • Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia.
    N Engl J Med
    . 2009;360:2302–2309.
See Also (Topic, Algorithm, Electronic Media Element)
  • Altered Mental Status
  • Delirium
CODES
ICD9
  • 294.10 Dementia in conditions classified elsewhere without behavioral disturbance
  • 294.20 Dementia, unspecified, without behavioral disturbance
  • 331.0 Alzheimer’s disease
ICD10
  • F02.80 Dementia in other diseases classified elsewhere without behavioral disturbance
  • F03.90 Unspecified dementia without behavioral disturbance
  • G30.9 Alzheimer’s disease, unspecified
DENGUE FEVER
Jessica Freedman
BASICS
DESCRIPTION
  • Dengue fever occurs secondary to dengue viral infection.
  • Most prevalent mosquito-borne viral infection.
  • Poorly understood immunopathologic response causes dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
  • DHF and DSS usually occur in patients with previous exposure to dengue virus.
  • Hemorrhagic manifestations occur after defervescence of fever.
  • Vascular permeability increases.
  • Plasma extravasates into extravascular space, including pleural and abdominal cavities.
  • Bleeding tendency
  • Shock may ensue.
  • Disseminated intravascular coagulation (DIC) may develop.
  • Dengue fever, DHF, and DSS are all self-limited.
  • World Health Organization—required criteria for the diagnosis of DHF:
    • Fever
    • Bleeding evidenced by one of the following: Positive tourniquet test, petechiae, ecchymosis, purpura, GI tract bleeding, injection site bleeding
    • Increased vascular permeability and plasma leakage as evidenced by an elevated hematocrit (>20%), decreased hematocrit >20% after volume replacement or pleural effusions, ascites or hypoproteinemia
    • Thrombocytopenia (<100,000/mm
      3
      )
  • World Health Organization—required criteria for diagnosis of DSS:
    • All 4 criteria of DHF +
    • Rapid and weak pulse
    • Narrow pulse pressure or hypotension for age
    • Cold, clammy skin
    • Restlessness
ETIOLOGY
  • Occurs in tropical and subtropical regions: Asia, Africa, Central and South America, and the Caribbean
  • Caused by dengue virus serotypes 1–4
  • Transmitted by mosquitoes: Aedes aegypti and Aedes albopictus
  • Incubation period of 3–14 days
  • There is only transient and poor cross protection among the 4 serotypes
DIAGNOSIS

Other books

Power Chord by Ted Staunton
The Greyhound by John Cooper
Cold Hard Magic by Astason, Rhys
One Taste by Allison Hobbs
Bred in the Bone by Christopher Brookmyre